| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e64d51c00a3b138567a44fc27bf0421 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-76 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2016-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75e92b6f9840f6d1dd1f786a8876ded
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_671f642f0a5a37272cd8f95dde29226c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_147f6eef95a7b5fb9b24b271a558f693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f79a0e87326fe8a4a40978b57b6fe9bf |
| publicationDate |
2016-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016243038-A1 |
| titleOfInvention |
Controlled-Release Compositions of Melatonin Combined with Sedative and/or Analgesic Ingredients |
| abstract |
Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3645014-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018068016-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849856-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111032059-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019031417-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10722494-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10869857-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4183388-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-3129079-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208247-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11351150-B2 |
| priorityDate |
2011-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |